Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Clinical Q&A

Barbara Holmes Gobel
CJON 2003, 7(1), 104-108 DOI: 10.1188/03.CJON.104-108

Question: What is the appropriate way to dose carboplatin (Paraplatin ®, Bristol-Myers Squibb, Princeton, NJ) when patients’ creatinine clearance (CrCl) are decreased or a concern exists about patients’ hematologic status (e.g., decreasing the dose after using a standard area under the curve [AUC] dosing or by choosing a lower AUC)?

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or